Menu Search
Equities

Flerie AB

  • Add to watchlist
  • Add to portfolio
  • Add an alert
1NP1:FRA

Flerie AB

Actions
  • Price (EUR)3.24
  • Today's Change-0.035 / -1.07%
  • Shares traded3.00
  • 1 Year change-21.10%
  • Beta-0.0149
Data delayed at least 15 minutes, as of Feb 12 2026 07:05 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Flerie AB, formerly InDex Pharmaceuticals Holding AB, is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company is an active long-term global biotech and pharmaceutical investor that managing a portfolio of companies in Europe, Israel, and the US. Flerie invests in companies across the entire value chain, providing exposure to opportunities across three segments: Product Development, Commercial Growth, and Limited Partnerships. The Product Development segment consists of early-stage biotech and pharma companies in product development. The Commercial Growth segment consists of companies that are already selling products or services and showcasing proof-of-concept with high growth and some that have already reached profitability. The Limited Partnerships segment provides benefits for the other two segments, including co-investment opportunities, and derisks Flerie’s investment portfolio.

  • Revenue in SEK (TTM)0.00
  • Net income in SEK-757.00m
  • Incorporated2016
  • Employees2.00
  • Location
    Flerie ABSkeppsbron 16STOCKHOLM 111 30SwedenSWE
  • Phone+46 812203850
  • Fax+46 850884739
  • Websitehttps://www.flerie.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		FLERIE:STO since
announced		Transaction
value
Lipum ABAnnounced18 Nov 202518 Nov 2025Announced-8.20%15.24m
Toleranzia ABDeal completed25 Mar 202525 Mar 2025Deal completed-19.89%4.53m
Data delayed at least 15 minutes, as of Feb 11 2026 17:00 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.